Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
A triple-action Formula for comprehensive respiratory relief
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Subscribe To Our Newsletter & Stay Updated
